10.1371/journal.pone.0126312 462 WangJ.LiuX.LiQ
Multiple groups have studied, characterised, and observed both compounds across in vitro, animal-model, and clinical-research contexts the combined-compound translation is not yet documented in clinical-trial-stage publications
However, sustained glutamatergic over-activity might lead to excitotoxic damage resulting in residual negative symptoms, cognitive dysfunction, and occupational and social impairment [4]
TB-500 promotes tissue repair through well-characterized actin-binding mechanism
Lijun Zhang, [email protected] These authors have contributed equally to this work This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Fatullaev EI, V.V.Bezrodnyi, Neelov IM